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Fabry disease (FD) is an X-linked lysosomal storage disorder caused by pathogenic variants in the 𝛼-galactosidase A (GLA) gene that leads to
reduced or undetectable 𝛼-galactosidase A enzyme activity and progressive accumulation of globotriaosylceramide and its deacylated form
globotriaosylsphingosine in cells throughout the body. FD can be multisystemic with neurological, renal, cutaneous and cardiac involvement
or be limited to the heart. Cardiac involvement is characterized by progressive cardiac hypertrophy, fibrosis, arrhythmias, heart failure
and sudden cardiac death. The cardiac management of FD requires specific measures including enzyme replacement therapy or small
pharmacological chaperones in patients carrying amenable pathogenic GLA gene variants and more general management of cardiac symptoms
and complications. In this paper, we summarize current knowledge of FD-related heart disease and expert consensus recommendations for
its management.
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Introduction
Fabry disease (FD) is an X-linked lysosomal storage disorder
caused by pathogenic variants in the 𝛼-galactosidase A (GLA) gene
that lead to reduced or undetectable 𝛼-galactosidase A (AGAL-A)
enzyme activity and progressive accumulation of glycosphin-
golipids, primarily globotriaosylceramide (Gb3), and its deacylated
form globotriaosylsphingosine (lyso-Gb3) in cells throughout the
body, including vascular endothelial and smooth muscle cells and
cardiomyocytes.1,2 Specific enzyme replacement therapy (ERT)

















. for FD administered by intravenous infusion became available
in 2001, and has been shown to clear Gb3 from the vascular
endothelium; its effects on cardiovascular manifestations have
been reviewed elsewhere.3–5 Novel therapy based on pharmaco-
logical chaperone is approved for FD patients carrying amenable
pathogenic variants6 and several treatments including modified
enzymes, substrate reduction therapy and gene therapy are in
development.7–10 Many studies have demonstrated a benefit in FD
when ERT is initiated early.11–13 In spite of ERT, several studies have
shown that some patients develop progressive structural heart
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disease, with complications refractory to treatment, particularly
when ERT is commenced in those with already advanced stages
of the disease with considerable left ventricular hypertrophy
(LVH) or fibrosis.13–17 In these patient, the benefit of ERT may
be attenuated. Consequently, cardiovascular complications now
represent the predominant cause of FD-related mortality.18
The aim of this project was to undertake a critical evaluation
of diagnostic and therapeutic procedures likely to be beneficial
in Fabry-related cardiac disease, based on a review of published
evidence. This document presents a summary of the review and
provides consensus recommendations for the management of
cardiovascular disease in FD.19–21
Methods
For the purposes of this document, a group of cardiologists and physi-
cians with expertise in the diagnosis and management of FD undertook
a comprehensive review of published studies on the prevalence, clini-
cal profile and management of cardiovascular complications in FD up
to 2019. Applicability of recommendations from general cardiovascu-
lar guidelines, including those for hypertrophic cardiomyopathy (HCM),
atrial fibrillation (AF), ventricular arrhythmias, cardiac resynchroniza-
tion and pacing, valvular heart disease, hypertension, and heart failure,
was also assessed.22 The level of evidence and the strength of each
recommendation were graded according to the methods used by the
European Society of Cardiology (ESC).23–25
Genetics of Fabry disease
Fabry disease is caused by pathogenic variants in the GLA gene
located on the X chromosome (Xq22.1). So far, over 1000 variants
distributed across the GLA gene have been identified, the majority
of which are missense. Many are unique or ‘private’ (i.e. confined
to one or a few families) and the frequency of de novo variants is
under 10%.26,27
Bi-directional sequencing (Sanger) of the seven coding exons
and the exon-intron boundaries of GLA is the gold standard for
molecular diagnosis. In females, multiplex ligation-dependent probe
amplification or quantitative polymerase chain reaction should be
performed if no mutation has been identified by Sanger sequencing,
to exclude large deletions or a copy number variation.26–28
High-throughput next-generation sequencing is increasingly used
with a number of gene panels incorporating GLA for the screening
of high-risk patient cohorts, including individuals with HCM. As a
result, many GLA variants of unknown significance (VUS) are being
identified.29–31 As a cautionary example, the p.Asp313Tyr change
results in a serum pseudodeficiency of AGAL-A activity and is
not disease-causing. Similarly, a number of GLA variants previously
thought to be disease-causing (e.g. p.Arg118Cys) have been shown
to be of uncertain significance or likely benign26,31,32 and therefore
reclassified.27 Individualized assessment of GLA variants is advised,
particularly in patients with evidence of FD pathology associated
with non-disease-causing variants, in whom additional mutations
should be sought.29–31 Detailed assessment of individual genetic



















































































.. familial history is essential to prevent delays in diagnosis and delayed
or inappropriate treatment.30,31
Female carriers of GLA pathogenic variants may also develop
disease, albeit in a delayed and generally milder form.33–36 Variable
clinical penetrance in women is partly explained by the process
of Lyonisation in which one of the two X chromosomes in each
cell is inactivated during embryonic development and remains
inactivated for all subsequent mitotic divisions. This results in
a mosaic pattern of expression with some cells expressing the
normal X chromosome and others the mutated GLA allele located
on the other X chromosome. Females with skewed X inactivation
expressing the mutated allele have similar disease severity as
hemizygous males.37,38
Epidemiology
Fabry disease affects all ethnicities, with some geographical clusters
based on founder mutations.39–41 The reported prevalence of FD
varies according to the screening method employed. Historical
data based on clinically diagnosed cases of predominant classic
FD suggested prevalence figures of 1 in 117 000.42 In contrast,
neonatal screening programmes have reported an unexpectedly
high incidence of disease-causing variants, ranging from 1:1250 to
1:7800.39,43–45
Most prevalence data are based on systematic screening of
high-risk populations with manifestations typical for advanced FD
such as HCM, cryptogenic stroke, or end-stage renal disease.46,47
The prevalence of FD in patients with unexplained LVH ranges from
0% to 12% in highly selected cohorts, but most studies suggest a
value around 0.5% to 1% in adult patients.27,48–62
Diagnosis of Fabry disease
The multisystem nature of FD means that patients can present with
a variety of symptoms and signs that, in context, provide diagnostic
clues. However, the absence of multiple organ manifestations does
not exclude the diagnosis.
Classic FD in males is characterized by onset of symptoms
in childhood, absent or severely reduced (<1% of normal)
AGAL-A enzyme activity and microvascular endothelial Gb3
accumulation.2,27,63 Typical manifestations include cutaneous
lesions (angiokeratoma), hypohidrosis, peripheral neuropathy (with
acral pain and painful febrile crises), premature stroke, microalbu-
minuria and proteinuria, renal insufficiency, and cardiomyopathy
(Figure 1).
A large number of patients have a late-onset phenotype man-
ifesting mostly as LVH or HCM. This so-called ‘cardiac variant’
has slower progression due to residual AGAL-A enzyme activ-
ity and less vascular endothelial Gb3 accumulation.
41,64 However,
the cardiac variant may occasionally present with some degree of
extra-cardiac involvement including stroke and renal dysfunction,
but the attribution of such complications to FD should be made
with caution, and a kidney biopsy should be considered for differ-
ential diagnosis in all cases exhibiting albuminuria/proteinuria with
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 1 Diagnosis. Flow chart showing a suggested approach to the diagnosis of Fabry disease (FD) in a patient with unexplained left
ventricular hypertrophy (LVH). Agal, 𝛼-galactosidase A; Gb3, globotriaosylceramide; GLA, 𝛼-galactosidase A gene; GLS, global longitudinal
strain; EMB, endomyocardial biopsy; RVH, right ventricular hypertrophy; VUS, variant of unknown significance.
deteriorating renal function, particularly in patients with concur-
rent risk factors for chronic kidney disease.40,65
As most cardiovascular signs of FD develop from the third
decade of life onwards, LVH in children and young adults is very
unlikely to be caused by FD.66 The probability of FD is also low
in the presence of an autosomal dominant inheritance pattern
(but not excluded in patients carrying simultaneously a sarcomeric
cardiomyopathy variant).67
Male patients with the classic form of disease have very low
(<1%) or absent AGAL-A activity and can be diagnosed reliably
by an enzymatic test in blood leukocytes or dried blood spot.46
Some male patients with late-onset, predominantly cardiac forms
of the disease have residual AGAL-A activity, although still far below
normal values, i.e. below 30% of normal.68
Heterozygous female patients from families with classical and
late-onset disease can have a wide range of clinical phenotypes
that vary with the type of GLA pathogenic variant and as a result
of skewed X-chromosome inactivation.37,38 In women with FD,
the activity of AGAL-A may be normal, meaning that a diagnosis
usually requires genotyping and accurate interpretation of detected
GLA variants. In both genders, suspicion of FD should be carefully
verified by confirmation of a disease-causing variant before ERT or
chaperone therapy is initiated.26,31,65,69
Currently, gene sequencing is the first-choice method for screen-
ing all female patients and for confirmation of the diagnosis in males
with low AGAL-A activity. Biopsy of an affected organ may be nec-
essary in women with signs and symptoms suggestive of FD in









































.. relative is available for investigation. Biopsy of an affected organ
provides definitive evidence of FD by demonstrating vacuoliza-
tion and typical lysosomal inclusions or ‘zebra’ bodies on electron
microscopy. However, evidence of lysosomal deposits does not
necessarily correlate with disease severity and organ damage.30,70,71
In many patients, Gb3 is elevated in plasma or urine
72,73 but
may be normal in patients with isolated cardiac involvement.52,74
Recently, assessment of lyso-Gb3 was proposed as a useful tool
for prediction of pathogenicity of detected VUS.75–77 It has been
demonstrated that pathogenic variants leading to classical FD are
associated with higher lyso-Gb3 levels as compared to later-onset
variants, which may even be associated with normal lyso-Gb3
levels.78 Benign GLA variants are associated with normal lyso-Gb3
levels (Table 1).2,26,27,31,33,43,47–51,63,69,75–80,82–99
Diagnosis of cardiovascular
involvement in Fabry disease
Electrocardiography
Children and adolescents may have subtle electrocardiographic
(ECG) changes100 and a left ventricular (LV) mass at the upper
limits of normal range reported for the general population, but
cardiovascular symptoms at this age are very rare.103–103 In adults,
the earliest clinical manifestations of Fabry-related cardiac disease
are ECG abnormalities associated with slowly progressive LVH that
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 1 Recommendations for the diagnosis of Fabry disease
Recommendations Class Level Ref.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Fabry disease should be considered in adults with unexplained LVH. IIa C 47–51
Assessment of AGAL-A activity is recommended as the first-line diagnostic
approach in men with clinically suspected FD.
I C 2,27,63,82,83
Sequencing of the GLA gene is recommended as the first-line diagnostic approach
in women with clinically suspected FD.
I C 2,33,83–88
Sequencing of the GLA gene is recommended in all patients to: (i) identify and
confirm the presence of a pathogenic or likely pathogenic variant; (ii) to test
for amenability to the pharmacological chaperone migalastat; and (iii) to assist
family cascade gene screening and prognostic assessment.
I C 2,89–92
Assessment of plasma lyso-Gb3 should be considered for assessment of disease
severity in FD patients or in the diagnostic algorithm for patients with GLA
genetic variants of unknown significance.
IIa C 26,75–80,93–96
Genetic counselling is recommended in all patients with FD, including those with
late-onset cardiac variants.
I B 2,43,69,97
Cascade genetic screening is recommended for all affected families. I C 2,31,89,97,98
In all cases of FD-related cardiomyopathy, clinicians should consider evaluation of
patients in centres with multidisciplinary teams that have expertise in the
diagnosis and management of FD.
IIa C 97–99
AGAL-A, 𝛼-galactosidase A; FD, Fabry disease; GLA, 𝛼-galactosidase A gene; LVH, left ventricular hypertrohy.
is clinically manifest after the third decade in males and fourth
decade in females.
A short PR interval without evidence of an accessory path-
way (most probably due to accelerated intra-atrial conduction),
repolarization abnormalities and signs of LVH (voltage criteria
and repolarization abnormalities – ‘strain’ pattern) are early
ECG features which precede the development of overt struc-
tural abnormalities in the heart.104 Voltage signs of LVH, strain
pattern and T-wave inversion in precordial leads are virtually
always present when FD cardiomyopathy has developed. In older
patients, sinus bradycardia and progressive conduction disease in
the atrio-ventricular (AV) node/His bundle and distal conduction
system are common and are an adverse prognostic marker.105
ST-segment depression and T-wave inversion may be associated
with the presence of fibrosis.105,106
Patients with FD are at high risk for developing symptomatic
bradycardia, chronotropic incompetence, AV block of any degree,
and supraventricular or ventricular arrhythmia. For this reason,
regular 24 h ambulatory ECG monitoring is recommended in
patients with cardiac involvement.105,107,108 Recent studies using
implantable loop recorders (ILR) have demonstrated a high preva-
lence of arrhythmia and conduction disturbances in patients with
FD despite normal initial 24 h Holter monitoring.109
The incidence of cardiac device implantation (pacemakers, defib-
rillators and loop recorders) in adult FD patients is between 1.07%
and 1.9% per year.14,105,108 The likelihood of pacemaker or defib-
rillator implantation increases in those with a severe phenotype,
particularly in the presence of myocardial fibrosis, in patients with
















































Echocardiography is the most useful method for diagnosing and
monitoring FD-related cardiomyopathy (Figure 2). Typical findings
include concentric LV remodelling or hypertrophy without rest-
ing LV outflow tract obstruction.110 However, asymmetric thick-
ening of the interventricular septum or apical hypertrophy is not
exceptional111 and dynamic LV outflow tract obstruction caused
by systolic anterior motion of the mitral valve can be provoked
by exercise112 or be present at rest, mimicking classical HCM.113
As myocardial fibrosis develops, the posterior and inferior LV wall
can thin and become hypokinetic or akinetic. Other typical fea-
tures include papillary muscle hypertrophy and right ventricular
wall thickening.114–118 The ‘binary sign’,115,116 characterized by a
bright endocardial layer and adjacent hypoechogenicity of the intra-
ventricular septum, may be seen in FD119 but similar findings occur
in other types of LVH and the sensitivity and specificity of this fea-
ture are low.120–122
Left ventricular ejection fraction is usually normal in FD, but can
be reduced in patients with extensive fibrosis, coexisting coronary
artery disease and ventricular dyssynchrony induced by conduction
disease.123 Systolic and diastolic tissue Doppler velocities at the
mitral annulus are decreased in cases with LVH but may overlap
with normal ranges in early stages of the disease.124–127
Myocardial strain and strain rate are usually abnormal in
patients with LVH,125 particularly in the posterolateral basal LV
segment, sometimes with post-systolic thickening.16,125,128–133
These findings may, in some cases, precede development of
significant LVH and may correlate with functional limitation.134
Myocardial performance (Tei) index is abnormal in patients with
overt cardiomyopathy.135
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Figure 2 Fabry flow chart. CAD, coronary artery disease; CRT, cardiac resynchronisation therapy; ECG, electrocardiogram; ERT, enzyme
replacement therapy; ETT, exercise treadmill test; ICD, implantable cardioverter-defibrillator; LV, left ventricular; LVOT, left ventricular outflow
tract; MRI, magnetic resonance imaging.
Diastolic function can be normal in the early phase of cardiac
involvement, but as the disease progresses, transmitral flow and
mitral annular tissue Doppler velocities become abnormal. A
restrictive filling pattern is rarely present and is usually associated
with advanced cardiomyopathy.123,124,130,136,137 Left atrial dilatation
is common.137 The assessment of diastolic function should be based
on a comprehensive integration of Doppler diastolic indices and
left atrial volume and interpreted in the context of clinical and
laboratory findings.138 Elevated LV filling pressures as assessed by
E/e′ ratio are associated with unfavourable prognosis.139
The mitral and aortic valves are often thickened, with
mild-to-moderate regurgitation. A small proportion of patients
have mitral valve prolapse or severe mitral regurgitation due to
leaflet degeneration that in some cases requires surgical repair.140
Stenotic valvular lesions are exceptional.140,141
Mild-to-moderate aortic dilatation involving the bulb and ascend-
ing aorta is frequently seen in advanced cases.142 The risk of aortic
dissection is not known but is almost certainly very low. Vascular
changes in FD are extensive, including ectasia of basilar or vertebral
arteries, increased carotid or radial artery intima–media thickness

































.. Cardiac magnetic resonance imaging
Cardiac magnetic resonance imaging (CMRI) provides an accu-
rate assessment of LV size, mass and geometry and can – with
the use of gadolinium contrast agents – visualize myocardial
fibrosis typically distributed in the mid-myocardial layer of the
posterolateral wall.148,149 The presence of extensive fibrosis is
associated with reduced response to ERT and with an increased
risk of arrhythmia.13,111,150 In some patients, particularly females,
areas of replacement fibrosis are detectable before development
of significant LVH.128,151 Thus, systematic use of CMRI may help
to reclassify patients in whom standard echocardiography fails to
detect relevant cardiac involvement.152
Cardiac magnetic resonance imaging can be useful in the detec-
tion of LV apical hypertrophy and to assess papillary muscle hyper-
trophy, an early marker of cardiac involvement.153,154 CMRI can
also be used to detect changes in the myocardium with native
(non-contrast) T1 mapping that reflects myocardial disease involv-
ing the myocyte and interstitium. Quantitative measures of myocar-
dial T1 in FD patients demonstrate low values particularly within
the interventricular septum, possibly due to the increase in myocar-
dial lipid content.155–159 Reduced T1 values are also reported
within the right ventricular wall.160 Of note, T1 reduction is
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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detectable in more than 90% of FD patients with LVH but also
in 40% patients without LVH.155,157,161 In pre-hypertrophic FD, the
presence of low T1 values correlates with early ECG, morpho-
logical cardiac changes, and predicts worsening of global disease
severity.162 In contrast, T1 values may become ‘pseudo-normal’ or
even increased within the posterolateral wall affected by fibrosis.
Unlike native T1, the extracellular volume in FD is typically normal
as FD is an intracellular storage disease.163 Imaging studies using
positron emission tomography/CMRI suggest an inflammatory pro-
cess linked to fibrosis as well as disturbances of energy metabolism
(31P spectroscopy).164–166
Endomyocardial biopsy
Endomyocardial biopsy (EMB) may be considered in patients with
VUS, high residual enzyme activity (>10%) and/or low lyso-Gb3
levels, to confirm or exclude FD as the cause of LVH.30,167–169
EMB may be useful whenever another cause of myocardial dam-
age is suspected or in unusual phenotypic presentations or clinical
evolution.170,171 EMB is not recommended to determine treatment
efficacy or to follow-up cardiac involvement. EMB should be evalu-
ated by expert pathologists and always include electron microscopy
studies to detect lamellar bodies and intracellular inclusions and to
exclude phenocopies of FD.
Electrophysiological studies
Invasive electrophysiological study (EPS) is recommended in
patients with documented persistent or recurrent supraventric-
ular tachycardia (atrial flutter, focal atrial tachycardia, AV nodal
re-entry tachycardia, accessory AV pathway-mediated tachycardia)
to guide therapy and may be considered in those who have evi-
dence from other non-invasive tests suggesting either sino-atrial
disease or AV block. EPS should also be considered in patients with
manifest pre-excitation (presence of delta-wave) in whom ablation
should be performed in the presence of symptoms such as syncope
or palpitations and/or when the refractory period of the accessory
pathway is ≤240 ms. In view of an increased risk of developing
AF, investigation of the anterograde and retrograde conduction
properties with determination of the effective refractory period of
the accessory pathway is recommended. EPS should include mea-
surement of the shortest pre-excited RR interval during induced
AF (or the shortest pre-excited RR interval during rapid atrial
pacing).172–175 The presence of a short PR interval as an isolated
finding is not an indication for an EPS176 and there is no evidence
that the routine use of EPS to determine risk of ventricular
arrhythmia in patients with FD provides clinical benefit.20
Laboratory tests
Routine laboratory testing aids detection of non-cardiac condi-
tions that cause or exacerbate ventricular dysfunction (e.g. thyroid
disease and diabetes mellitus) and secondary organ dysfunction.
Regular monitoring of renal function and detection of microalbu-



















































































.. in patients with known cardiac variant mutations, as renal dys-
function can occur both due to FD-related renal involvement and
other causes.65,177 Severe renal dysfunction is associated with an
increased risk of cardiac complications.139
Plasma inflammatory markers, including C-reactive protein and
interleukin-6, are elevated in FD patients and are associated with
increased symptom and disease burden (LVH and fibrosis) as well
as progressive disease.178,179
Plasma lyso-Gb3 values decrease with ERT and chaperone ther-
apy. An increase can be seen in patients treated with ERT that
have developed antibodies and treatment resistance. Therefore,
lyso-Gb3 may be used for treatment monitoring.
180 Recently, an
association between the presence of neutralizing anti-drug antibod-
ies and clinical progression has been demonstrated.181,182
Plasma N-terminal pro B-type natriuretic peptide (NT-proBNP)
is elevated in patients with cardiac manifestations and cor-
relates with symptom class, echocardiographic surrogates of
elevated LV filling pressure (left atrial size and E/e′) and LV
mass. Although NT-proBNP concentrations may be raised
in patients without echocardiographic evidence of LVH, the
highest values are encountered in patients with LVH, diastolic
dysfunction, reduced T1 relaxation times on CMRI mapping
and myocardial fibrosis.183–185 Elevated high sensitivity tro-
ponin indicates advanced disease and a worse prognosis186
(Table 2)1,13,76,81,90,104,111,112,156,157,161,167,169,170,178,184,186–215.
Assessment of cardiac symptoms
Heart failure
Heart failure symptoms are reported in up to a quarter of patients
in FD registries66 and large cohort studies.14 In the majority of
patients, LV ejection fraction is normal and symptoms are caused
by increased LV diastolic pressures. In a minority of patients with
advanced disease, there may be systolic dysfunction or significant
valvular disease. In all symptomatic patients, Doppler echocar-
diography during exercise in the standing, sitting or semi-supine
position is recommended to detect provocable LV outflow tract
obstruction and exercise-induced mitral regurgitation in line
with the ESC guidelines for HCM.90 In patients presenting with
significant conduction impairment and progressive decline of
systolic function, signs of asynchrony should be evaluated. As
pulmonary involvement is also common in FD and muscular
fatigue/myopathy may be present,216 breathless patients should
undergo spirometry.217–220
In some patients, chronotropic incompetence probably caused
by autonomic nervous dysfunction can be a contributing factor to
exertional dyspnoea.105,191,221,222 For this reason, symptom-limited
exercise stress testing or cardiopulmonary exercise stress testing
if available is useful in the differential diagnosis of dyspnoea.223,224
Chest pain
Although large disease registries do not report an increased inci-
dence of acute coronary syndromes in FD (a history of acute
myocardial infarction is reported in only around 2%), patients
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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Table 2 Recommendations for diagnosis and monitoring of cardiac disease in patients with Fabry disease
Recommendations Class Level Ref.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ECG and heart rhythm monitoring
A standard 12-lead ECG is recommended at first clinical evaluation, with the
development of new symptoms, and every 6–12 months in adult patients.
I B 90,104,187
24 h ambulatory ECG monitoring (or longer if available) should be considered
at initial assessment and every 6–12 months in adult patients to document
atrial and ventricular arrhythmias.
IIa C 90,188–191
Cardiac imaging
2D and Doppler echocardiography is recommended in all patients at first
clinical visit, with the development of new symptoms, and every 12 to
24 months.
I B 90,192
In symptomatic patients with LVH, Doppler echocardiography during exercise
in the standing, sitting or semi-supine position is recommended to detect
provocable LV outflow obstruction and exercise-induced mitral
regurgitation.
I C 90,112,193–199
In the absence of contraindications, contrast enhanced CMRI should be
considered in all adult patients in order to assess cardiac anatomy,
ventricular function and the presence of myocardial fibrosis at initial
evaluation.
IIa C 90,111,157,161,200–205
In the absence of contraindications, contrast enhanced CMRI may be
considered every 5 years in adult patients in order to assess the
progression of fibrosis and LV function depending on disease severity and
CMRI availability.
IIb C 13,90
Non-contrast T1 mapping may be considered in adult FD patients to detect




Endomyocardial biopsy with sample evaluation including electron microscopy
should be considered in patients with LVH, genetic variants of unknown
significance in the GLA gene, and significant residual AGAL-A activity
(>10%) in order to confirm a diagnosis of FD.
IIa C 167,169,170
Biomarkers
Regular assessment of renal function and urine analysis for
microalbuminuria/proteinuria is recommended in all patients.
I C 207–209
Measurement of plasma BNP/NT-proBNP is recommended in symptomatic
patients with suspected heart failure.
I B 178,184,210,211
High-sensitivity cardiac troponin (hs-cTnT or hs-cTnI) may be considered for
the assessment of disease severity.
IIb C 186,212,213
Measurement of lyso-Gb3 may be considered as a prognostic marker,
particularly in patients with genetic variants of unknown significance and/or
late-onset genetic variants.
IIb C 1,76,81,214,215
2D, two-dimensional; AGAL-A, 𝛼-galactosidase A; BNP, B-type natriuretic peptide; CMRI, cardiac magnetic resonance imaging; ECG, electrocardiogram; FD, Fabry disease;
Gb3, globotriaosylceramide; GLA, 𝛼-galactosidase A gene; hs-cTnI, high-sensitivity cardiac troponin I; hs-cTnT, high-sensitivity cardiac troponin T; LV, left ventricular; LVH, left
ventricular hypertrohy; NT-proBNP, N-terminal pro B-type natriuretic peptide.
have abnormal vessels due to endothelial and medial Gb3 storage
and may develop epicardial coronary stenotic lesions.225,226 In
many patients, symptoms probably result from microvascular
dysfunction.168,227 Stress testing is of limited value in patients with
baseline ECG changes228 and coronary artery imaging should be
considered in all patients with angina in accordance with the ESC
guidelines on chronic coronary syndromes.229,230 Perfusion imaging
with positron emission tomography shows a decrease in coro-














.. arteries, including females without significant LVH, but contributes
little to routine clinical evaluation and decision-making.227,231,232
Palpitations
Palpitations are reported by 15% to 43% of adult patients
depending on sex and stage of the disease.66 The most frequent
cause is probably atrial arrhythmia and all patients with frequent or
prolonged episodes should undergo ambulatory ECG monitoring
© 2020 The Authors. European Journal of Heart Failure published by John Wiley & Sons Ltd on behalf of European Society of Cardiology.
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for AF. When episodes are prolonged or highly symptomatic, an
ILR should be considered.109
Syncope
A history of syncope in adult patients ranges between 3.6% and
5.6% in men and 1.7% and 2.6% in women.66 Patients with FD
experience syncope for many reasons, including autonomic dys-
function, sinus node dysfunction, complete heart block and sus-
tained ventricular tachyarrhythmia. Patients with syncope should
undergo 12-lead ECG, standard upright exercise test and 48 h
ambulatory ECG monitoring.191,223 Exercise stress echocardiog-
raphy should be considered, particularly in patients with exer-
tional or postural syncope, to detect provocable LV outflow tract
obstruction.112,113 In patients with unexplained syncope, an EPS and
an ILR may be considered111,237 (Table 3).90,109,172–175,223,224,233–241
Management of cardiac
complications
General aspects of Fabry disease
management
The management of FD requires a broad understanding of the
disease and in some important aspects differs from the usual stan-
dard of care in other cardiovascular diseases. General measures
for cardiovascular prevention, including lifestyle advice and smok-
ing cessation in line with current guidelines for cardiovascular dis-
ease prevention and blood pressure control.242,243 Special attention
should be paid to the management of dyslipidaemia.244 Patients
with FD and preserved functional capacity should not be discour-
aged from participating in recreational sports but should be advised
against intense competition. In young patients with classic FD, spe-
cial attention should be paid to maintain adequate hydration and
avoid overheating, which may provoke febrile painful crises.245
Enzyme replacement therapy
Enzyme replacement therapy targets the underlying process caus-
ing organ damage in FD. Studies have shown that ERT can reduce
endothelial Gb3 inclusions in the heart, but evidence for clear-
ance of Gb3 from cardiomyocytes is less convincing.
4,168,246 Most
evidence suggests that the heart responds less well to therapy
when disease is advanced, particularly in patients with extensive
fibrosis.4,13,168,246,247
Enzyme replacement therapy is indicated in all symptomatic
patients with classical disease, including children, at the earliest
signs of organ involvement. Three preparations of recombinant ERT
are currently available: agalsidase alfa (Replagal®, Shire), agalsidase
beta (Fabrazyme®, Sanofi Genzyme) and agalsidase beta (Fabagal®,
ISU Abxis). The major difference between them is the prescribed
dose, which is fivefold higher for agalsidase beta (1.0 mg/kg every
2 weeks) than for agalsidase alfa (0.2 mg/kg every 2 weeks).
There is evidence from long-term follow-up studies248,249 and



















































































.. reduces the burden of clinical events when started early in the
course of the disease.34 There are also data showing that the heart
responds less well to therapy when disease is advanced13,247 or
when antibodies to the exogenous enzyme have developed.251,252
There is limited evidence for a beneficial effect of ERT in late-onset
cardiac variants.167,253
Mild LVH may partially regress in classical254,255 and cardiac
variant patients167 and one study has suggested that LVH may be
prevented by early therapy.13 However, there are no data showing
that ERT prevents myocardial fibrosis150 and patients with extensive
myocardial fibrosis probably respond less well in terms of functional
improvement.13,247
Chaperone therapy
Orally administered migalastat is an alternative treatment
option6,256–259 reserved for patients with specific ‘amenable’
GLA pathogenic variants. Binding of the pharmacological chap-
erone, migalastat, to the active site of 𝛼-galactosidase stabilizes
some mutant enzymes, thus facilitating proper trafficking to lyso-
somes, where dissociation of migalastat allows 𝛼-galactosidase to
catabolize accumulated substrates.258 Although data are limited,
migalastat has been shown to slow organ damage. Furthermore,
a promising, albeit modest decrease in LV mass index has been
observed.6,256,257,260,261 The ability of migalastat to mitigate the
glomerular filtration rate decline associated with some amenable
GLA variants has recently been questioned.261
Heart failure
Heart failure symptoms should be treated according to current
ESC recommendations but with several caveats. As patients with
FD are prone to sinus and AV node dysfunction, beta-blockers and
ivabradine should be used with caution and be monitored using
repeated Holter recordings.23 Angiotensin-converting enzyme
(ACE) inhibitors, angiotensin receptor blockers (ARBs), and min-
eralocorticoid receptor antagonists are indicated in patients with
systolic impairment, paying special attention to hyperkalaemia
and renal function in patients with nephropathy. In symptomatic
patients with preserved ejection fraction, the use of spironolac-
tone may be considered.262,263 There is no published experience
with sacubitril/valsartan in FD.
In patients receiving pacemakers, there is a concern about
the long-term effects of non-physiological right ventricular pac-
ing. Although significant ventricular dysfunction in unselected
patients develops rarely,264 the main predictors of this unfavourable
outcome include LVH and heart failure.265 Two-year data from
the PACE trial suggest that biventricular pacing for bradycardia
in patients with preserved ejection fraction may lead to more
favourable outcomes as compared to right ventricular pacing
alone.266 For this reason, cardiac resynchronisation therapy should
be considered in patients with FD that require pacing, particularly
when the LV ejection fraction is impaired.
Classic FD may be associated with some degree of peripheral
oedema, often due to lymphoedema or renal disease rather than
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Table 3 Recommendations for assessment of symptoms
Recommendations Class Level Ref.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Exercise testing
Cardiopulmonary exercise stress testing (or standard treadmill or bicycle
ergometry when unavailable) should be considered to assess the severity
and mechanism of exercise intolerance and change in systolic blood
pressure and heart rate.
IIa C 90,223,224,234
Chest pain
Coronary angiography (or CT coronary angiography) is recommended in all
patients with angina CCS class ≥II.
I C 235–238
Invasive coronary angiography is recommended in adult survivors of cardiac
arrest, in patients with sustained ventricular tachyarrhythmia and in patients
with severe stable angina (CCS class III) and unstable angina.
I C 90,236,239
Syncope and palpitation
12-lead ECG, upright exercise test, resting and exercise 2D and Doppler
echocardiography, and at 48 h ambulatory ECG monitoring are
recommended in patients with unexplained syncope, to identify the cause
of their symptoms.
I C 90,233,240,241
A prolonged ECG monitoring or preferably an ILR should be considered in
patients with recurrent episodes of unexplained syncope.
IIa C 90,109,233,241
An ILR may be considered in patients with palpitations or recent stroke in the
presence of negative ambulatory ECG monitoring.
IIb C 90,109,233,241
Invasive EPS may be considered in patients with unexplained syncope to
exclude conduction abnormalities.
IIb C 172–175
2D, two-dimensional; CCS, Canadian Cardiovascular Society; CT, computed tomography; ECG, electrocardiogram; EPS, electrophysiological study; ILR, implantable loop
recorder.
ventricular failure. In these instances, it is often unresponsive to
diuretic therapy.267,268
Angina
Coronary artery disease in FD patients should be managed conven-
tionally, but caution is required when using negative chronotropic
drugs such as beta-blockers, verapamil, diltiazem, and ivabradine
due to the increased risk of bradycardia. CMRI using late gadolin-
ium enhancement visualization of fibrosis should be considered
for the assessment of myocardial viability taking into account the
non-ischaemic character of replacement fibrosis within the pos-
terolaterlal LV wall. FD patients with significant LVH represent
high-risk operative candidates for coronary artery bypass grafting
and percutaneous coronary intervention and should be managed
in experienced centres.
Management of left ventricular outflow
tract obstruction
Patients with exertional symptoms caused by LV outflow tract
obstruction should be managed in accordance with the ESC guide-
lines on HCM.90 However, as FD patients may be prone to develop
symptomatic bradycardia, drugs affecting AV node conduction
(beta-blockers, verapamil, disopyramide) should be used with cau-
tion. In addition, disopyramide requires dose adjustment according









































. and surgical) have been successfully performed in severely symp-
tomatic FD patients resistant to medical therapy.113,199,269,270
Atrial fibrillation
In cross-sectional studies, approximately 5% of males and 3% of
females have AF and the incidence of new AF is around 6% per
annum.14 AF and atrial flutter may be partly responsible for the
increased incidence of stroke in FD.63 In contrast, a low prevalence
of AF is seen in young stroke patients (<30 years), reflecting the
fact that cardiac involvement is usually mild or absent before the
fourth decade.271 However, prolonged ECG monitoring should still
be considered in FD patients.
Rhythm control
Maintenance of sinus rhythm involves both pharmacological and
interventional therapies,272 but is often challenging in the presence
of an evolving atrial substrate and significant limitations of available
drugs. Amiodarone should be limited to the management of poorly
tolerated acute episodes as chronic therapy may induce phospho-
lipidosis and potentially reduce the effect of ERT.273–275 Little is
known about the effect of dronedarone on endosomal/lysosomal
trafficking and function and it is contraindicated in New York Heart
Association class III–IV heart failure patients and impaired renal
function (estimated glomerular filtration rate <30 mL/min). Sotalol
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is contraindicated in decompensated heart failure and when creati-
nine clearance is <10 mL/min276 and flecainide should be used cau-
tiously when estimated glomerular filtration rate is <35 mL/min.277
Furthermore, flecainide and propafenone are both contraindicated
in patients with depressed ventricular function and heart failure.
Experience with catheter ablation of AF is sporadic in FD. Extrap-
olating from HCM patients, a high rate of AF relapse and need for
repeat procedures is to be expected, particularly in older patients
with left atrial dilatation.278
Anticoagulation
None of the available scoring systems for estimating stroke risk are
validated in FD and extrapolation from HCM suggests that they
should not be used in FD. The use of the HAS-BLED score for
estimation of bleeding risk may be useful, although the age criterion
is not appropriate particularly in male patients.22
Anticoagulation with vitamin K antagonists should be considered
in all patients with any form of AF or atrial flutter. Systematic data
on direct oral anticoagulants (DOACs) in FD are lacking. However,
given reports of cerebral microbleeds in FD, DOACs could have
a potential advantage over warfarin as they are associated with
reduced risks of intracranial bleeding.271,279 In addition, the use
of DOACs may reduce the risk of warfarin-induced nephropathy
and slow the progression of renal function decline.280,281 Special
attention should be paid to dose reduction and contraindications
of DOACs in patients with impaired renal function, as well as
drug interactions specific for each of these agents.282 In patients
unable to use anticoagulation, left atrial appendage closure may be
considered.21
Rate control
Due to the tendency of FD patients to develop bradycardia
and AV conduction abnormalities, repeated Holter monitoring
is recommended to verify the adequacy of rate control. The
administration of any bradycardia-inducing drugs should be done
with extreme caution with regular ambulatory ECG monitoring
(Table 4).69,90,271,273,279–281,283–294
Bradycardia and atrio-ventricular block
Symptomatic bradycardia caused by sinus node dysfunction and
AV block is relatively common in FD. In a series of 204 patients,
the 5-year cumulative incidence of anti-bradycardia pacing was
8%. The need for pacing was best predicted by QRS duration
and PR interval.105 Symptomatic bradycardia should be treated in
accordance with the current ESC guidelines.25,90 Due to the high
risk of AV node dysfunction, dual chamber pacemakers should be
implanted unless patients are in permanent AF. If AV block is caused
by AV node blocking drugs, their indication and dose should be
reviewed and the need for pacing re-evaluated after adjustment.
The benefit of rate-responsive pacing in treating exercise intol-
erance is uncertain. However, highly symptomatic patients with
proven chronotropic incompetence may benefit. Although some



















































































.. ventricular pacing in preserving systolic function and prevent-
ing LV remodelling,266,295 this approach is not fully supported
by current guidelines. Cardiac resynchronisation therapy with
pacemaker implantation should be considered in symptomatic
patients with ejection fraction <50% and QRS prolongation (QRS
>120 ms).90,296 In those who have progressed to LV dysfunction
(ejection fraction ≤35%), cardiac resynchronisation therapy should
be considered in accordance with the current ESC Guidelines
(Table 5).25,90,105,266,295–299
Ventricular arrhythmia
Non-sustained ventricular tachycardia (NSVT; defined as three or
more ventricular premature beats at a rate of ≥100 bpm and
lasting <30 s) is a common finding on ambulatory ECG moni-
toring in FD.189 Its prevalence increases with age and correlates
with progression of late gadolinium enhancement on CMRI.150
Asymptomatic runs of NSVT do not usually require anti-arrhythmic
therapy. Unlike patients with idiopathic or sarcomeric HCM, the
relation between NSVT and sudden cardiac death (SCD) risk is
unknown. However, in the majority of myocardial diseases, fibrosis
extent along with presence or rapid and repetitive NSVT are corre-
lated to SCD occurrence and such association was also suggested
in FD.15
Documented sustained monomorphic ventricular tachycardia
(≥30 s) is rare and in some patients its origin may be associated
with areas of myocardial scarring.109,111 Coronary artery disease
should be excluded in all patients with prolonged or symptomatic
episodes. In patients with evidence of a focal origin, EPS and abla-
tion may be considered. Patients with poorly tolerated ventricular
tachycardia should receive implantable cardioverter-defibrillator
(ICD) therapy.20
Prevention of sudden cardiac death
A recent meta-analysis of data from 13 studies suggests that cardio-
vascular mortality is now the major cause of mortality in patients
with FD.188 An ICD is recommended in patients who have sur-
vived a cardiac arrest due to ventricular tachycardia or fibrillation,
or who have spontaneous sustained ventricular tachycardia causing
syncope or haemodynamic compromise, and have a life expectancy
of >1 year.20
At present, there are insufficient data to determine the prog-
nostic value of clinical risk markers used in patients with idio-
pathic or sarcomeric HCM and so in patients with FD the recom-
mended ESC risk tool (HCM RISK-SCD) should not be used.300
Current data suggest that patients with advanced LVH and exten-
sive (and rapidly progressing) fibrosis may be candidates for ICD
implantation.150,188,189,301 ICD implantation may also be considered
in patients with significant LVH and unexplained syncope.
Decisions concerning the ICD in primary prevention should be
made on an individual patient basis, guided by the age and general
health of the patient, personal preference, socio-economic factors
and the psychological impact of therapy.18,188 EPS with programmed
ventricular stimulation does not seem to contribute effectively to
SCD risk stratification in FD and its routine use in patients with
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Table 4 Recommendations for the management of atrial arrhythmia
Recommendations Class Level Ref.
Maintenance of sinus rhythm rather than rate control is recommended for patients with FD and
AF.
I C 90,283,284
Regular 48 h Holter monitoring is recommended in patients with left atrial enlargement and in
case of unexplained palpitations to detect AF.
I C 69,90,285
The use of CHADS2 and CHA2DS2-VASc scores is not recommended to assess the need for
anticoagulation in patients with FD and AF.
III C 90,286
All patients with AF and atrial flutter should receive anticoagulation with DOACs or VKAs
unless contraindicated.
I C 90,287–292
DOACs should be considered as the first-line choice in FD patients without contraindications
resulting from renal function impairment.
IIa C 271,279–281
The use of aspirin monotherapy is not recommended to protect against cardioembolic stroke. III C 90
Combination therapy with aspirin 75–100 mg plus clopidogrel 75 mg daily may be considered for
stroke prevention in patients for whom OAC therapy is unacceptable or contraindicated and
where there is a low risk of bleeding.
IIb C 90,293
Left atrial appendage closure may be considered in patients unable to receive anticoagulation
therapy.
IIb C 90
Amiodarone may interfere with lysosomal metabolism and its chronic use should be considered
only if other treatments are ineffective.
IIa C 69,273,294
In patients with AF treated with rate control, Holter ECG monitoring should be used to assess
rate response and to detect bradycardia.
I C 90
Ablation therapy for AF may be considered as for the general population. IIb C 90
AF, atrial fibrillation; DOAC, direct oral anticoagulant; ECG, electrocardiogram; FD, Fabry disease; OAC, oral anticoagulation; VKA, vitamin K antagonists.
Table 5 Recommendations for cardiac pacing in Fabry disease
Recommendations Class Level Ref.
Dual-chamber pacing may be considered in symptomatic patients with FD and
proven chronotropic incompetence.
IIb C 25,105
CRT-P implantation should be considered in symptomatic patients with a
pacing indication and an LVEF <50% and QRS prolongation (QRS >120 ms).
IIa C 25,90,296
CRT-P implantation may be considered in symptomatic patients with a pacing
indication and an LVEF ≥50% irrespective of QRS duration.
IIb C 266,295,298,299
CRT-P, cardiac resynchronisation therapy with pacemaker; FD, Fabry disease; LVEF, left ventricular ejection fraction.
syncope or symptoms suggestive of malignant arrhythmia is not
recommended20 (Table 6).14,90,108,109,150,188–190,302–307
Other measures
Angiotensin-converting enzyme inhibitors or ARBs (if ACE
inhibitors are not tolerated) should be used in all patients with
hypertension, significant microalbuminuria/proteinuria and LV
systolic dysfunction.308 Their use in patients with LV outflow tract
obstruction should be avoided if possible.90
There is no evidence of statin efficacy in FD but in the absence
of any other supporting data, statins should be used according to
current consensus guidelines.242,309 The use of low-dose aspirin
is recommended in secondary prevention in patients with symp-
tomatic atherosclerosis.
Drugs interfering with lysosomal function, and possibly with FD
specific therapies, like amiodarone and hydroxychloroquine, should



























In general, patients with FD require lifelong follow-up to detect
changes in symptoms, arrhythmia occurrence, and heart failure
progression. Clinical evaluation should be performed at baseline
and whenever new symptoms develop. Cardiological follow-up
should be part of a multidisciplinary team approach involving other
specialties and should be performed in centres with experience of
FD.2,69,310
In children, the progression of cardiac disease is slow and cardiac
manifestations rare.100 Therefore, cardiological re-evaluation may
be less frequent (every 2–3 years). However, in classic FD the
follow-up should be more frequent since early disease-specific
treatment therapy may be beneficial.311,312
In adult men over the age of 20 years and women aged over 30,
clinical re-evaluation should be performed on an annual basis. As a
minimum, evaluation should consist of a clinical assessment, ECG,
echocardiography and Holter monitoring. CMRI evaluation may be
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Table 6 Recommendations for implantable cardioverter-defibrillators
Recommendations Class Level Ref.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
ICD implantation is recommended in patients with FD who have survived a cardiac
arrest due to VT or VF, or who have spontaneous sustained VT causing syncope or
haemodynamic compromise, and have a life expectancy of >1 year.
I C 90,108,302–306
ICD implantation should be considered in patients with advanced hypertrophy and
fibrosis requiring pacemaker implantation, and a life expectancy of >1 year.
IIa C 14,109,188,189
ICD may be considered in patients with advanced hypertrophy and fibrosis and/or
rapidly progressing fibrosis, and a life expectancy of >1 year.
IIb C 108,109,150,307
ICD may be considered in patients with severe LVH and unexplained syncope or
NSVT on ambulatory ECG monitoring.
IIb C 108,188,190
ECG, electrocardiogram; FD, Fabry disease; ICD, implantable cardioverter-defibrillator; LVH, left ventricular hypertrophy; NSVT, non-sustained ventricular tachycardia; VF,
ventricular fibrillation; VT, ventricular tachycardia.
considered routinely every 2–5 years before the onset of cardiac
features and then every 2–3 years in patients with progressive
disease or earlier based on the clinical picture.
Conclusions
Cardiac disease is a major cause of mortality and morbidity in
classical and variant FD. Specific treatment strategies including
enzyme replacement or small pharmacological chaperone have
limited efficacy in advanced cases with irreversible organ damage,
so that it is not only important to diagnose FD early and avoid
any delays in treatment initiation, but it is also vital that patients
receive timely assessment and treatment of cardiac symptoms and
complications.
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